Date: 2015-10-00
Type of information: Completion of patient enrollment
phase: 3
Announcement: completion of patient enrollment
Company: Foresee Pharmaceuticals (Taiwan, USA - DE)
Product: FP-001 (leuprolide mesylate)
Action
mechanism: LHRH agonist.
Disease: advanced prostate carcinoma
Therapeutic area: Cancer - Oncology
Country: United States, Austria, Czech Republic, Germany, Lithuania, Poland, Slovakia, Taiwan
Trial
details: The study will evaluate if leuprolide mesylate for injectable suspension (LMIS 50 mg) is safe and effective in the treatment of subjects with advanced prostate carcinoma, when administered as two injections six months apart. (NCT02234115)
Latest
news: * In October 2015, Foresee Pharmaceuticals announced that its FP-001 drug for prostate cancer completed enrollment of 137 patients in its pivotal phase III registration trial.* In August 2014, Foresee Pharmaceuticals announced that its FP-001 pipeline candidate is entering into global phase 3 registration trial.
